Cargando…

Prescribing of FDA-approved and compounded hormone therapy differs by specialty

OBJECTIVE: To determine the prescribing patterns of general practitioners (GPs), obstetrician/gynecologists (OB/GYNs), and wellness physicians (WPs) of menopausal hormone therapy (HT) for both compounded (CHT) and Food and Drug Administration (FDA)-approved products, using a survey of US physicians....

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantine, Ginger D., Archer, David F., Graham, Shelli, Bernick, Brian A., Mirkin, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott-Raven Publishers 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028143/ https://www.ncbi.nlm.nih.gov/pubmed/27648594 http://dx.doi.org/10.1097/GME.0000000000000683

Ejemplares similares

SAT-LB003 Nonsmokers Benefit from Lower Doses of an Estradiol/Progesterone Combination: Results of the REPLENISH Trial
por: Constantine, Ginger, et al.
Publicado: (2019)

Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey
por: Pinkerton, JoAnn V., et al.
Publicado: (2016)

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms
por: Santoro, Nanette, et al.
Publicado: (2019)

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women
por: Constantine, Ginger D., et al.
Publicado: (2017)

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial
por: Simon, James A., et al.
Publicado: (2017)

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
por: Kaunitz, Andrew M., et al.
Publicado: (2020)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol
por: Archer, David F., et al.
Publicado: (2017)

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review
por: Constantine, Ginger D., et al.
Publicado: (2019)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone
por: Mirkin, Sebastian, et al.
Publicado: (2019)

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries
por: Constantine, Ginger D, et al.
Publicado: (2016)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
por: Constantine, Ginger D., et al.
Publicado: (2019)

Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR
por: Kingsberg, Sheryl A., et al.
Publicado: (2017)

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
por: Constantine, Ginger D., et al.
Publicado: (2020)

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)(∗)
por: Mirkin, Sebastian, et al.
Publicado: (2020)

Systemic estradiol levels with low-dose vaginal estrogens
por: Santen, Richard J., et al.
Publicado: (2019)

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
por: Kagan, Risa, et al.
Publicado: (2018)

Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy
por: Pinkerton, JoAnn V., et al.
Publicado: (2016)

SAT-001 Clinically Meaningful Effects of E2/P4 Oral Capsule in Treating Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial
por: Black, Denise R., et al.
Publicado: (2020)

Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert
por: Mirkin, Sebastian, et al.
Publicado: (2021)

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
por: Simon, James A., et al.
Publicado: (2019)

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial
por: Liu, James H., et al.
Publicado: (2020)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy
por: Pickar, James H., et al.
Publicado: (2015)

Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling
por: Young, John, et al.
Publicado: (2021)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Physical characteristics and properties of estradiol softgel vaginal inserts
por: Simon, James A., et al.
Publicado: (2019)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury
por: Li, Haixia, et al.
Publicado: (2023)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b3f210tas1mennhs5c62g2n6ba